We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
- Zydus Lifesciences has signed exclusive licensing agreements with both RK Pharma and Synthon BV for separate novel 505(b)(2) oncology products targeting the US market. - The RK Pharma partnership targets a market opportunity of 6.2 million units and focuses on reducing dosing errors and enhancing healthcare professional compliance. - The Synthon collaboration addresses a $1.5 billion addressable market and aims to provide reduced pill burden and enhanced patient compliance through additional product strengths. - Both products are expected to be filed for regulatory approval in 2026 under the 505(b)(2) pathway, leveraging existing safety and efficacy data.
